Plasma-Treated Hydrogel Compositions for Localized RONS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for biocompatible compositions that can effectively deliver reactive oxygen and nitrogen species (RONS) to target sites in the body for cancer treatment while minimizing damage to healthy tissues and facilitating bone tissue regeneration.
Innovation Solution
A composition comprising a polymer aqueous solution, a bioceramic material containing calcium, and RONS, which are generated through cold atmospheric plasma treatment, allowing localized delivery and release of RONS to kill cancer cells without harming healthy cells, and promoting bone tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RONS are delivered locally to the target site, then cancer cell killing efficiency is improved, but diffusion in extracellular fluids and blood flow reduces delivery effectiveness
Solution Approach 1:
The patent uses plasma-activated liquid as an intermediary carrier to transfer RONS from the plasma source to the target tissue. This liquid mediator allows controlled delivery of RONS while minimizing uncontrolled diffusion in bodily fluids, directly resolving the contradiction between delivery effectiveness and confinement stability.
Solution Approach 2:
The patent extracts RONS from the plasma phase and transfers them to a liquid phase that can be injected and confined at the target site. This separation allows the RONS to be delivered locally without the harmful effects of uncontrolled plasma application, improving both delivery effectiveness and local confinement.
2Reliability
If high concentrations of RONS are used to kill cancer cells, then cancer treatment efficacy is improved, but damage to healthy cells increases
Solution Approach 1:
The patent applies different RONS concentrations to different locations: high concentration at the tumor site for effective cancer cell killing, and low or zero concentration in surrounding healthy tissues to avoid damage. This spatial variation in RONS concentration directly resolves the contradiction between treatment efficacy and healthy tissue protection.
Solution Approach 2:
The plasma-activated liquid serves as a mediator that can be precisely injected into the tumor site, allowing high RONS concentrations to be delivered only where needed. This controlled delivery mechanism enables high cancer cell killing efficiency while protecting healthy cells from exposure.
3Ease of operation
If minimally invasive therapy is used, then patient trauma is reduced, but ability to deliver sufficient RONS to target site is compromised
Solution Approach 1:
The patent uses liquid-phase RONS delivery through injection, a hydraulic approach that allows minimally invasive administration. The plasma-activated liquid can be injected directly into the tumor site using standard injection techniques, providing sufficient RONS delivery while maintaining minimal invasiveness.
Solution Approach 2:
The patent changes the physical state of RONS from gas phase in plasma to dissolved state in liquid, enabling delivery through injection. This parameter change allows the same RONS to be delivered via minimally invasive injection while maintaining sufficient concentration and quantity at the target site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition selectively targets and kills cancer cells while maintaining the viability of healthy cells and supports bone tissue regeneration, offering a minimally invasive therapy for bone cancer and osteosarcoma.
Implementation Method 1
CAP generate reactive oxygen and nitrogen species (RONS) which can be transferred to liquids
Implementation Method 2
APPs formed in air generate reactive oxygen and nitrogen species (RONS), which can be transferred to liquids through secondary reactions
Implementation Method 3
injection of a liquid in the body results in fast diffusion due to extracellular fluids and blood flow. Therefore, the development of efficient vehicles which allow local confinement and delivery of RONS to the diseased site is a fundamental requirement
Data Source
Figure 1~2B
Figure 3A~4
Figure 5~6
AI summary
The present invention relates to a composition comprising a polymer aqueous solution, a bioceramic material and reactive oxygen and nitrogen species (RONS) and its use for the treatment of bone cancer and/or bone tissue regeneration.